Tvardi Therapeutics’ (TVRD) Buy Rating Reiterated at BTIG Research

Tvardi Therapeutics (NASDAQ:TVRD)‘s stock had its “buy” rating reiterated by research analysts at BTIG Research in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $15.00 price target on the stock. BTIG Research’s price objective would suggest a potential upside of 422.10% from the company’s current price.

Other analysts also recently issued research reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, April 10th. HC Wainwright started coverage on Tvardi Therapeutics in a research note on Monday, June 8th. They set a “buy” rating and a $9.00 target price for the company. Finally, Wall Street Zen cut Tvardi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 4th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Tvardi Therapeutics has an average rating of “Moderate Buy” and an average price target of $39.80.

Tvardi Therapeutics Stock Performance

Shares of Tvardi Therapeutics stock traded up $0.86 during trading hours on Tuesday, hitting $2.87. The company’s stock had a trading volume of 53,991,611 shares, compared to its average volume of 503,905. The business has a 50 day moving average price of $3.05 and a two-hundred day moving average price of $3.53. Tvardi Therapeutics has a 12-month low of $1.50 and a 12-month high of $43.65. The company has a market cap of $26.95 million, a PE ratio of -0.91 and a beta of 0.39.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its earnings results on Friday, May 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.08). As a group, research analysts anticipate that Tvardi Therapeutics will post -2.39 earnings per share for the current year.

Hedge Funds Weigh In On Tvardi Therapeutics

Several large investors have recently bought and sold shares of TVRD. Arax Advisory Partners lifted its position in shares of Tvardi Therapeutics by 277.2% during the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after acquiring an additional 6,173 shares during the period. JPMorgan Chase & Co. acquired a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth about $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in Tvardi Therapeutics in the 2nd quarter worth approximately $43,000. HRT Financial LP purchased a new stake in shares of Tvardi Therapeutics in the fourth quarter valued at $47,000. Finally, XTX Topco Ltd acquired a new position in shares of Tvardi Therapeutics during the 4th quarter valued at about $55,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.